Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment and Follow-up of Patients With Non-small Cell Lung Cancer (NSCLC) Treated With Nivolumab Under the French Temporary Authorization for Use (ATU) Program

NCT02933346 is registered in ClinicalTrials.gov with Intergroupe Francophone de Cancerologie Thoracique as lead sponsor.

NCT NCT02933346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02933346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment and Follow-up of Patients With Non-small Cell Lung Cancer (NSCLC) Treated With Nivolumab Under the French Temporary Authorization for Use (ATU) Program
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Phase
Observational
Overall status
Completed
Start date
September 30, 2016
Completion date
December 15, 2020
Enrollment
907 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

long-term adverse effects, nivolumab, non-small cell lung cancer